Can oral sirolimus therapy prevent in-stent restenosis?
Thomas M Schiele
Correspondence Interventional Cardiology Division, Hospital of the Ludwig-Maximilians-University, München Innenstadt, Ziemssenstrasse 1, 80336 Munich, Germany
Email Thomas.Schiele@med.uni-muenchen.de
This article has no abstract so we have provided the first paragraph of the full text.
Coronary stent implantation has become standard practice for the treatment of coronary artery disease. This therapy is limited, however, by a high incidence of in-stent restenosis (about 30%), which is associated with significant mortality, morbidity and cost. Drug-eluting stents infused with either sirolimus or paclitaxel have emerged as a potential solution and effectively reduce neointimal proliferation in de novo and in-stent restenotic lesions, yielding restenosis rates of only 10%.1, 2 This technology is expensive, especially when applied to multivessel disease requiring more than one stent. Thus, a systemic antiproliferative regimen might be preferable.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
